Humacyte engineered vessel beats standard fistula in Phase 3 dialysis trial (opens in new tab)

Humacyte presented Phase 3 V012 results at the Society for Vascular Surgery Vascular Annual Meeting in Boston, showing its acellular tissue-engineered vessel, or ATEV, outperformed autologous arteriovenous fistula for women on dialysis. Women who received the ATEV averaged 220 catheter-free days in the first year versus 129 days for av fistula, a statistically significant difference […] The post appeared first on <a href="